Sionna Therapeutics, Inc.
NGM: SIONLive Quote
📈 ZcoreAI Score
Our AI model analyzes Sionna Therapeutics, Inc.'s price action across multiple timeframes using regression channels and statistical scoring.
Get SION Z-Score →About Sionna Therapeutics, Inc.
Healthcare
Biotechnology
Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transmembrane conductance regulator (CFTR) that has completed Phase 2 trial; navocaftor (SION-3067), a potentiator that has completed Phase 2 trial; SION-109, an intracellular loop 4 directed CFTR corrector that has completed Phase 1 trial; SION-2851, a TMD1-directed CFTR corrector that has completed Phase 1 trial; SION-451, which is nucleotide-binding domain 1 stabilizer in Phase 1 trial; and SION-719, which is nucleotide-binding domain 1 stabilizer in Phase 2a proof-of-concept trial. The company was formerly known as Sling Therapeutics, Inc. and changed its name to Sionna Therapeutics, Inc. in July 2021. Sionna Therapeutics, Inc. was incorporated in 2019 and is headquartered in Waltham, Massachusetts.
📊 Fundamental Analysis
Sionna Therapeutics, Inc. demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
Return on Equity (ROE) is -31.8%, which indicates that capital utilization is currently under pressure.
At a current price of $37.89, SION currently trades near the top of its 52-week range (81%) (Range: $7.76 - $45.00).
🏥 Financial Health
🔴
Profit Margin
Weak
🔴
Debt/Equity
Elevated
🔴
Return on Equity
Weak
Key Financials
Market Cap
$1.70B
Trailing P/E
--
Forward P/E
-14.68
Beta (5Y)
--
52W High
$45.00
52W Low
$7.76
Avg Volume
298K
Day High
Day Low